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Abstract: The risk of onset of cancer is influenced by poorly controlled chronic 
inflammatory processes. Inflammatory diseases related to cancer development include 
inflammatory bowel disease, which can lead to colon cancer, or actinic keratosis, 
associated with chronic exposure to ultraviolet light, which can progress to squamous cell 
carcinoma. Chronic inflammatory states expose these patients to a number of signals with 
tumorigenic effects, including nuclear factor kappa B (NF-κB) and mitogen-activated 
protein kinases (MAPK) activation, pro-inflammatory cytokines and prostaglandins release 
and ROS production. In addition, the participation of inflammasomes, autophagy and 
sirtuins has been demonstrated in pathological processes such as inflammation and cancer. 
Chemoprevention consists in the use of drugs, vitamins, or nutritional supplements to 
reduce the risk of developing or having a recurrence of cancer. Numerous in vitro and 
animal studies have established the potential colon and skin cancer chemopreventive 
properties of substances from marine environment, including microalgae species and their 
products (carotenoids, fatty acids, glycolipids, polysaccharides and proteins). This review 
summarizes the main mechanisms of actions of these compounds in the chemoprevention 
of these cancers. These actions include suppression of cell proliferation, induction of 
apoptosis, stimulation of antimetastatic and antiangiogenic responses and increased 
antioxidant and anti-inflammatory activity. 
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1. Introduction 
Cancer constitutes one of the leading causes of death, with an estimated 14.1 million new cases of 
cancer registerd worldwide in 2012, and it is expected to increase in the coming years [1]. The risk of 
onset of cancer is influenced by previous chronic inflammatory processes; epidemiological studies 
have reported that up to 25% of diagnosed tumours present, in their origin or evolution, an important 
inflammatory component [2]. Chronic inflammation is associated with extrinsic and intrinsic factors 
that increase the risk of developing cancer; the first consists of microbial infections, such as 
Helicobacter pylori and its association with gastric cancer [3], tobacco and its relation with lung 
cancer [4] or ultraviolet (UV) light and its association with skin tumors [5]. Intrinsic factors, driven by 
genetic alterations, include mutations in oncogenes, like RAS oncogenes, in tumor suppressor genes, 
such as adenomatosis polyposis coli (APC) and p53 [6] and in DNA repair genes, such as MSH-2, 
MSH-6 and PMS-2 [7], which lead to cell transformation and maintain autonomous proliferation of 
transformed cells. In addition, intrinsic defects comprise alterations of the immune system [8,9].  
In some types of cancer, transformed cells produce inflammatory mediators, generating an inflammatory 
microenvironment in tumors for which there is no underlying inflammatory condition [10]. 
Until now, cancer research has focused on the search for curative treatments, and few studies have 
aimed to develop preventive strategies. Chemoprevention is an old concept that consists in the use of 
drugs, vitamins, or nutritional supplements to reduce the risk of developing or having a recurrence of 
cancer. Considering the important role of inflammation in the origin and evolution of a variety of 
tumors, the interest in chemoprevention has markedly increased in the last years [11]. Carcinogenesis 
of common epithelial tumours, including lung, colon, pancreas, ovary, skin, prostate and breast, which 
are responsible for most deaths, is a slow process that could start twenty years before the first 
symptoms appear. This long period is very suitable for using chemopreventive strategies that block the 
development of invasive and/or metastatic disease. With these objectives, cancer chemoprevention 
uses natural, synthetic or biological substances to reverse, suppress or prevent either the initial phase of 
carcinogenesis or the progression of neoplastic cells to cancer [12,13]. Previous studies have indicated 
that cyclooxygenase 2 (COX-2) inhibitors reduce the risk of colon, lung or skin cancer, and other 
findings suggest that statins, or certain biguanides such as the classical metformin, are effective 
chemopreventive agents [14–16]. Epidemiological and experimental studies suggest that certain 
dietary components identified from fruits and vegetables help to maintain a proper balance in cell 
proliferation and are capable of preventing carcinogenesis. Phytonutrients have received considerable 
attention due to their low cost and high safety [17].  
Traditionally, Earth’s natural products have been studied to a great extent for drug development and 
have been used therapeutically. Cragg et al. [18] conducted a detailed study about the importance of 
natural products as sources of new drugs in the last 25 years. Particularly, they found that 47% of 
anticancer drugs were of natural origin or directly derived from nature, and up to 70% could be 
considered structurally related to natural compounds. Early research focused on inland compounds, but 
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in the last 30 years the need for new therapeutic molecules has given rise to a vast number of studies in 
marine invertebrates and microbes. In this regard, many new interesting compounds, which are 
commonly referred to as marine natural products, have been discovered. The large diversity found in 
the marine environment represents a huge source from which to isolate new molecules from microbes 
such as bacteria, cyanobacteria, fungi, algae, microalgae or small invertebrates [19]. This review 
summarizes the major bio-products obtained from microalgae (carotenoids, fatty acids, glycolipids, 
polysaccharides and proteins) with potential interest in the treatment/prevention of inflammatory 
diseases and colon and skin cancer. 
2. Microalgae as a Source of Bioactive Molecules 
Microalgae are a vast group of unicellular prokaryotic and eukaryotic organisms that are mainly 
autotrophic, but there are a few taxa such as Polytoma sp., Polytomella sp., or Prototheca wickerhamii 
that have been described as heterotrophical with degenerated chloroplasts [20,21]. Despite the fact that 
the number of new species described is increasing yearly, only a small percentage of them have been 
investigated so far. In fact, only a few phytoplanktonic species are available to grow on a large scale, 
including Dunaliella, Chlorella, Isocrysis, Nannochloropsis, Nannochloris, Chlamydomonas, 
Haematococcus and Spirulina, among others [19,22]. 
These phytoplanktonic organisms have colonized every type of ecological niche, and they constitute 
the major group of living organisms in terms of species diversity in both terrestrial and marine waters [23]. 
Traditionally, the therapeutic compounds have been obtained from inland organisms, but in the last 
decades the need for new pharmacologic molecules has given rise to a broad number of studies in 
marine environment in both animals and phototrophic organisms such as microalgae [19,24]. The 
major interest in microalgae is the capacity to modulate their metabolism according to environmental 
conditions. Moreover, microalgae are acknowledged to be a diverse source of bioactive molecules that 
play physiological roles for themselves and their environment. In addition, microalgae have been 
found to produce new molecular structures due to seawater composition in halogen atoms [25]. Being 
photoautotrophic, their simple growth requirements and the capacity to modulate their metabolism, 
make them attractive for demand by the pharmaceutical, food, cosmetic or biodiesel industries. In fact, 
microalgae are rich in high fatty acids, protein, antioxidant pigments and polysaccharides.  
In this line, microalgae are also used to feed fish in aquaculture or animal consumption as dietetic  
supply [26].  
Microalgae have been shown to produce a huge variety of bioactive products with potential 
commercial values. Nevertheless, only a few of them, such as β-carotene and astaxanthin, have been 
produced at industrial scale [27], due to their low production in native microalgae and the difficulty in 
isolating them by economically feasible means [28,29]. For several years, scientific effort in this area 
has been undertaken to select high-yield strains, to optimize cultivation or to use genetic engineering to 
modify the strains to get high-value-added products [30–32]. In this context, chemicals as metabolic 
triggers or enhancers that are able to directly modulate cellular metabolism have been proposed and 
applied in various commercially viable microalgae [33]. In this regard, Franz et al. [34] demonstrated 
that several chemicals such as epigallocatechin gallate, cyclin-dependent kinase 2 inhibitor and 
cycloheximide could act as enhancers to produce an increase of intracellular lipids in several species of 
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Nannochloropsis and Phaeodactylum tricornutum. On the other hand, genetic modification is also  
a helpful tool to obtain a high-yield production of bioactive compounds. In this line, a short exposure 
to UVC radiation led to a significant increase in total cellular lipid content, including eicosapentaenoic 
acid (EPA), in Nannochloropsis sp., microalgae identified as a highly efficient producer of n-3 fatty  
acids [35]. Moreover, the use of auxins has been shown to regulate growth and metabolite production 
of several microalgae, such as Chorella vulgari [36]. Thus, more studies are required to establish the 
optimal culture conditions to obtain high concentrations of bioproducts. Many of these biomolecules 
such as fatty acids, carotenoids, proteins, polysaccharides, phenolic compounds, amongst others, have 
attracted the interest of the pharmaceutical industry based on their anti-oxidant, anti-inflammatory or 
anticarcinogenic activities, which make them very promising tools for the prevention of inflammatory 
diseases or cancer (Table 1).  
Table 1. Compounds obtained from microalgae and their biological activities. 
Compound Source Activity References 
CAROTENOIDS 
β-Carotene Dunaliella salina  
Haematococcus sp. 
Antioxidant  
Pro-vitamin A  
Anti-inflammatory  
Anticancer 
[30,37,38] 
Astaxanthin 
Haematococcus 
pluvialis  
Chlorella zofigiensis 
Chlorococcum sp. 
Antioxidant  
Anti-inflammatory  
Anticancer 
[39,40]  
Lutein 
Dunaliella salina  
Chlorella sorokiniana 
Chlorella 
prothecoides 
Antioxidant  
Anti-inflammatory  
Anticancer 
[41–43]  
Violaxanthin 
Dunaliella tertiolecta 
Chlorella ellipsoidea 
Anti-inflammatory  
Anticancer 
[44,45]  
Zeaxanthin 
Synechocystis sp.  
Chlorella 
saccharophila 
Antioxidant  
Anti-inflammatory 
[46,47]  
Fucoxanthin 
Phaeodactylum 
tricornutum  
Isochrysis sp. 
Anticancer [48,49] 
FATTY ACIDS 
Eicosapentaenoic acid (EPA) Tetraselmis sp. 
Antiinflammatory  
Anti-angiogenic 
[50,51]  
Docosahexaenic acid (DHA) Tetraselmis sp. 
Antiinflammatory  
Anti-angiogenic 
[52,53]  
Docosapentaenoic acid (DPA) 
Nannochloropsis 
oculata 
Antiinflammatory [52,54]  
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Table 1. Cont. 
GLYCOLIPIDS 
Monogalactosyldiacylglycerol 
(MGDG) 
Gymnodinium 
mikimotoi  
Stephanodiscus sp  
Pavlova lutheri  
Stephanodiscus sp. 
Anticancer  
Antioxidant 
[55,56]  
Digalactosyldiacylglycerol 
(DGDG) 
Stephanodiscus sp 
Anticancer  
Antioxidant 
[57,58] 
Sulfo-quinovosyl-acyl-glycerol 
(SQAG) 
Stephanodiscus sp 
Anticancer  
Antioxidant 
[57,59] 
POLYSACCHARIDES 
Sulphated extracellular 
polysaccharide 
Diatom  
Phaeodactylum 
tricornutum 
Anti-inflammatory  
Inmunomodulating 
[60] 
Sulphated polysaccharide  
Β-(1,3)-glucan 
Chlorophyte  
Chlorella 
stigmatophora  
Chlorella vulgaris 
Anti-inflammatory  
Inmunomodulating  
Anticancer 
[60,61]  
Sulphated polysaccharide 
Prasinophyte  
Tetraselmis suecica 
Anti-inflammatory [62]  
Sulphated polysaccharide 
Haptophyte  
Isochrysis galbana 
Anticancer [63]  
Sulphated polysaccharide 
Rhodophyte  
Porphydium sp.  
Anti-inflammatory  
Inmunomodulating  
Anticancer 
[64]  
Sulphated polysaccharide 
Dinoflagellate  
Gyrodinium 
impudicum 
Anti-inflammatory  
Inmunomodulating  
Anticancer 
[65]  
Extracellular polysaccharide   
s-Spirulan 
Cyanobacteria  
Arthrospira platensis 
Anticancer [66]  
PROTEIN AND PEPTIDES 
Phycobiliproteins 
Spirulina platensis  
Porphyridium sp. 
Antioxidant  
Anti-inflammatory  
Anticancer 
[67,68]  
Peptides 
Chlorella pyrenoidosa 
Cyanobacteria 
Antioxidant  
Anti-inflammatory  
Anticancer 
[69,70]  
OTHER COMPOUNDS 
Amides Lyngbya majuscule Anticancer [71]  
Quinones Calothrix sp. Anticancer [72]  
Phenolic compounds 
Spirulina maxima  
Chlorella ellipsoidea 
Nannochloropsis sp 
Antioxidant [73,74]  
Tocopherols Porphydium sp. Antioxidant [75]  
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3. Colorectal Cancer as a Consequence of Chronic Inflammatory Disorder 
3.1. Molecular Pathways of Colon Carcinogenesis 
Colorectal cancer (CRC) is the third most common cancer, with an estimate average incidence  
of 42.4 per 100,000 men and women per year, and the third leading cause of death related to cancer 
disease, being diagnosed each year in about 1 million people worldwide [76]. Inflammatory intestinal 
conditions implicated in the origin of neoplasia have been the object of numerous clinical, genetic and 
molecular studies in humans and experimental animal models. Although the association between 
ulcerative colitis (UC) and elevated risk for CRC is clear, there have been some debates about whether 
Crohn’s disease (CD) possesses a similar risk [77]. Many papers have reported that the duration of the 
disease, its severity, the association with other inflammatory diseases including sclerosant colangitis, 
or certain treatments, are factors that concede inflammation an advantageous role in colon 
carcinogenesis [78]. 
Experimental animal models of inflammatory bowel disease (IBD) have been widely tested, but only 
a few are applicable in the study of the inflammation and associated cancer [79,80]. The histological 
changes in IBD patients who develop neoplasms correspond to the inflammation-dysplasia-cancer 
sequence. In this progression, the histological classification has been established by Riddle [81] and 
Pascal [82]: (i) Undefined for dysplasia/probably negative; (ii) Undefined for dysplasia/probably 
positive; (iii) Low grade dysplasia; (iv) High grade dysplasia; (v) Carcinoma. However, the identification 
of dysplasia in intestinal inflammatory diseases represents a huge challenge for both clinicians and 
pathologists, so a clear diagnosis of dysplasia in IBD is not always possible. Possible markers, such as 
p53 and alpha-methylacyl coenzyme, have been used. The combination of these two markers is 
positive in 75.8% for cancers and 30.3% for undefined biopsies for dysplasia, while it is only positive 
in 0.6% for non-neoplastic epithelium. The suspect lesions can be visible macroscopically or only 
microscopically. Bird and Good [83] described focal points of aberrant crypts such as preneoplastic 
lesions in rodents treated with carcinogen. It has been proved that these aberrant crypts can be high or 
flat lesions; high crypts are raised above the surrounding epithelium with round, elongated, open 
lights; and flat crypts are small or slightly enlarged lesions with compressed open lights. β-catenin 
expression has been studied in both high and flat aberrant crypts; this protein is found in the cytoplasm 
in flat lesions, and it moves to the cytoplasm and nucleus in polypoidal lesions, being an important 
early event in the development of colitis-associated cancer [84].  
The molecular mechanisms to explain how a chronic inflammatory state affects tumor development 
are beginning to be elucidated. These mechanisms comprise the production of inflammatory mediators 
such as chemokines and cytokines, including tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), 
IL-6, IL-10, IL-11, IL-17, IL-18, IL-22 and IL-23, prostaglandins (PGs) produced by the coordinated 
enzymatic activity of COX and membrane-associated PGE synthase-1, nitric oxide (NO) released by 
inducible nitric oxide synthase (iNOS), or signaling pathways including signal transducer and activator 
of transcription 3 (STAT3) and nuclear factor kappa B (NF-κB). In this regard, NF-κB has been shown 
to have a role in uncontrolled cell growth, inhibition of apoptosis and induction of metastasis and 
angiogenesis [85]. Pharmacological strategies for its regulation have been designed, and some of them 
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are directed towards the control of the mechanisms that trigger a persistent activation, as occurs in 
inflammatory pathologies. 
Regarding PGs, these molecules have been found in different types of tumors, including colon 
adenocarcinomas [86] or squamous cell carcinomas [87], and have tumorigenic effects, including 
stimulation of cell growth and angiogenesis, inhibition of apoptosis and suppression of immune 
system. NO radical has a complex behaviour depending on the synthesizing enzyme, levels produced 
and the tissue microenvironment. One of the main mechanisms by which NO regulates the function of 
the target proteins is through the S-nitrosation of thiols, which involves the conversion of thiol groups 
in proteins to form S-nitrosothiols. This is a mechanism for post-translational regulation of protein, but 
in cancer the consequences of S-nitrosylation are not fully understood and present dual  
functions: protective effect by inducing cell death or metastasis and epigenetic changes [88]. In 
addition to NO radicals, reactive oxygen species (ROS) are formed during the oxygen mitochondrial 
metabolism and have important roles in cell signaling and homeostasis; however, under stress 
circumstances ROS levels can increase dramatically, resulting in severe damage in cell structures. [89]. 
The innate immune system, in response to harmful stimuli, such as pathogens, dead cells or irritants, 
starts defence programs to repair damaged tissue. Insufficient inflammation can result in persistent 
infection by pathogens, while excessive inflammation can cause chronic inflammatory pathologies, 
including arthritis, diabetes, inflammatory bowel disease, or skin diseases [90]. The innate immune 
function depends upon the recognition of pathogen-associated molecular patterns (PAMPs), derived 
from invading pathogens, and damage-associated molecular patterns (DAMPs), induced as a result of 
endogenous stress, by pattern-recognition receptors (PRRs). Nucleotide binding and oligomerization 
domain (NOD)-like receptors (NLRs), included in the family of PRRs, are found in the cytoplam and 
are essential for detecting invading pathogens and initiating the innate immune response [91]. Some 
types of these receptors form a multiprotein complex called inflammasome, with the NLRP3 
inflammasome being the best characterized. NLRP3 can be activated by a wide range of stimuli, 
including pathogens and their components, chemical irritants and endogenous danger signals such as 
adenosine triphosphate (ATP) [92]. NLRP3 activation is also induced by the production of ROS, 
whose predominant source generated by danger signals is most probably the mitochondria [93]. Upon 
stimulation, NLRP3 associates with the adaptor protein ASC, and induces caspase-1 activation and 
subsequent proteolytic maturation of pro-inflammatory cytokines IL-1β and IL-18 (Figure 1) into their 
mature active forms [94]. 
Recent studies have shown that inflammasomes regulate the gastrointestinal (GI) microbiome and 
can thereby affect host susceptibility to diseases beyond the GI tract, including obesity and diabetes [95]. 
Inflammasomes also maintain the integrity of the intestinal epithelium and promote its repair, being 
important factors in the pathogenesis of IBD. In this regards, it has been observed that polymorphisms 
in genes that encode IL-18 and IL-18 receptor accessory protein are associated with increased 
susceptibility to CD [96]. Given its association with a number of inflammatory diseases, NRLP3  
type inflammasome has been of great interest; polymorphisms in this inflammasome, which impaired 
IL-1β production by lipopolysaccharide (LPS)-stimulated monocytes, were linked to increased 
susceptibility to CD. Chen and Nuñez [97] have recently revised complementary information on the 
role of the inflammasome in IBD. 
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Figure 1. Inflammasome activation and role in carcinogenesis. Reactive oxygen species 
(ROS) liberated by mitochondria initiate inflammasome assembly, which promotes the 
maturation of the inflammatory cytokines (IL-1β and IL-18) through caspase 1 activation 
with the participation of multiprotein oligomers, as the scheme of NLRP3 subtype shows. 
A microenvironment of chronic inflammation promotes cancer development. 
In pathological conditions, mitochondrial malfunctions induce the activation of NLRP3 
inflammasome, and some inflammatory diseases are associated with defects in these organelles and 
their elimination by autophagy (mitophagy). In IBD pathogenesis, particularly in CD, a a key role of 
IL-1β, IL-18 and the inflammasome has been reported [98]. In animal models of IBD, genetic defects 
in autophagy induce hyperactivation of the inflammasome, and the application of anti IL-1β and IL-18 
in animals with colitis by dextran sulfate sodium (DSS) reduce colon damage [99]. These observations 
are consistent with other studies showing that the silencing of genes that regulate autophagy, including 
Beclin 1, ATG5, or microtubule-associated protein light chain 3 (LC3), cause spontaneous NLRP3 
activation and subsequent secretion of IL-1β [100]. 
In IBD-associated colorectal cancer, the activation of the inflammasome is a consequence of the 
inflammatory pathology and plays a key role in tumorigenesis. In animals IL18−/− or deficient in its 
receptor, the combination of azoxymethane (AOM) and DSS showed a large number of tumors, and 
the authors suggested a role of NLRP3 in the supression of such tumors [101]. Similarly, Zaki et al. [98] 
have demonstrated that caspase-1-deficient mice have increased the number of tumors, similar to 
NLRP3 mutants, which is associated with a decreased production of IL-18 and activation of STAT1. 
NLRP6 is expressed particularly in the hematopoietic system, and similar to NLRP3, could protect 
against the development of tumors; this result is remarkable because of the high expression of NLRP6 
in the intestinal epithelium. Regarding the NLRC4 inflammasome, findings are contradictory, with 
some studies showing negative regulatory effects [102] and others reporting no significant effect [103]. 
A recent retrospective analysis of gene expression from human patients [104] to elucidate the 
contribution of NLR family members in IBD and cancer revealed that NLRP1 was significantly 
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dysregulated; complementary data in Nlrp1b deficient mice confirmed that NLRP1 attenuates GI 
inflammation and tumorigenesis. Both results identify NLRP1 as an essential mediator of the host 
immune response during intestinal inflammation and cancer. 
Sirtuins are a group of highly phylogenetically conserved proteins that catalyze the deacetilation of 
target proteins, in a nicotinamide adenine dinucleotide (NAD+)-dependent manner [105]. In mammals, 
there are seven sirtuins with diverse cellular locations that regulate a variety of physiopathological 
processes, such as aging, inflammation and cancer, through deacetylation of key transcription factors, 
enzymes and proteins [106]. Sirtuin 1 (SIRT1), the most studied mammalian homologue, has demonstrated 
its relation with inflammation through modulation of the activity of NF-κB [107]. More recently, 
SIRT6 has been shown to be implicated in DNA repair, telomere maintenance, glucose homeostasis, 
inhibition of obesity induced by metabolic dysfunction and attenuation of inflammation [107,108]. 
Autophagy is a biological process involved in recycling long-lived proteins and damaged 
organelles, including mitochondria, to maintain cellular homeostasis. This process is initiated by the 
formation of double-membrane bound vacuoles, the autophagosomes, which envelop cytoplasmic 
contents and deliver them to autolysosomes [109]. Autophagy is regulated by nutrient-sensing 
pathways, including the mammalian target of rapamycin (mTOR), AMP-activated protein kinase 
(AMPK) and SIRT1. AMPK is a major metabolic energy sensor, which is activated by a decreased 
ATP/AMP ratio, such as occurs during nutrient starvation and hypoxia [110]. Accumulating evidence 
indicates that SIRT1 and AMPK mutually regulate each other and both are required for autophagy 
induction (reviewed in Garcia-Mauriño et al. [111]).  
Autophagy is suggested to be involved in the regulation of IBD and CRC. Autophagy malfunction 
is associated with an alteration of both innate and adaptative immune responses, defects in bacterial 
clearance and dysfunction of goblet and Paneth cells; all these perturbations are related to IBD and 
CRC pathogenesis [111]. It has been reported that the initial activation of this process may have  
a beneficial role in disease, since it diminishes the risk of damage by elimination of anomalous 
proteins or injured organelles. It has been reported that mice lacking essential components of the 
autophagic machinery, such as the autophagy-related 16-like 1 (Atg16L1) are highly susceptible to 
colitis [99]. As regards to cancer, it is not clear whether autophagy suppresses or facilitates tumor 
development. As a tumor suppressing mechanism, autophagy serves as an alternative to apoptosis to 
eliminate transformed cells. However, it has also been reported that autophagy may facilitate cancer 
cells growth and survival under stressful conditions such as nutrient starvation and low-oxygen 
conditions, especially in the inner parts of the tumors [112]. This process is suggested to be mediated 
by AMPK, which is activated as a consequence of decreased intracellular ATP level, as occurs under 
nutrient deprivation or hypoxia. In this situation, AMPK-mediated induction of autophagy could be 
advantageous for the tumor development by allowing the tumor cells to cope with the stress [113]. On 
the other hand, AMPK, in addition to activating autophagy, has shown cytotoxic activity in several 
cancer cell lines; this supports the fact that AMPK is a tumor suppressor, and thus a potential 
therapeutic target. In this regard, metformin, an antidiabetic drug that activates AMPK, reduces the 
incidence of tumors including CRC in treated patients [114]. 
A role of SIRT1 in tumorigenesis is still controversial because this protein has been shown to act as 
both tumor suppressor and tumor promoter. In this line, it has been reported that SIRT1 overexpression 
in the intestine reduces polyp formation, a potential precursor to CRC, in Apcmin/+ mice, possibly 
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through deacetylation of β-catenin [115]. However, SIRT1 deficiency led to increased tumor formation 
in p53-null mice [116] and in a mouse xenograft model of colon carcinoma [117]. Moreover, a 
previous paper demonstrated that SIRT1 expression correlated with stage of different human CRC, 
detecting the lowest SIRT levels in advanced adenocarcinomas and metastatic tissue samples [117,118]. 
However, the results of other investigations have reported a protumoral activity of SIRT1 in CRC. In 
this line, a recent study has demonstrated an increased SIRT1 expression in different colonic lesions, 
including polyps, adenomas and neoplasia, which was associated with the grade of malignancy and 
invasiveness [119]. Further in line with tumor-promotive function, SIRT1 stimulated constitutive Wnt 
signaling and Wnt-induced cell migration in the colon cancer cell lines HT-29, HCT116, RKO and 
DLD-1 [120]. SIRT6 has shown several catalytic activities including deacetylation, deacylation and 
ribosylation. This protein has been recently categorized as a tumor suppressor because its depletion 
alters the levels of acetylated histone H3. The deacylation activity has been endorsed to the regulation 
of TNF-α secretion. SIRT6 also undergoes auto-ribosylation that might deliver to a self-regulation of 
catalytic functions, and also enhances poly (ADP-ribose) polymerase 1 (PARP1)-dependent DNA 
repair under oxidative stress and aging. Recent studies evaluated that SIRT6 deficiency is associated 
with various diseases including inflammation and different types of cancer [121]. These data suggest 
that SIRT6 may be a promising target for cancer prevention and therapy. 
3.2. Microalgae as a Source of Biomolecules with Potential in IBD and Colon Cancer 
3.2.1. Carotenoids 
Carotenoids are natural isoprenoid pigments biosynthesized by all photosynthetic plants, protists, 
and bacteria, as well as some heterotrophic bacteria, some fungi and some invertebrates. Animals are 
generally unable to synthesize carotenoids and require a dietary intake to meet daily health demands. 
The main subtypes of carotenoids are carotenes (hydrocarbon carotenoids) and xanthophylls 
(oxygenate derivatives). Carotenoids comprise many of the yellow, orange and red pigments of nature, 
including many fruits, vegetables, flowers, butterflies and crayfish [122]. Five major carotenoids are 
synthetically produced on an industrial scale (lycopene, β-carotene, canthaxanthin, zeaxanthin and 
astaxanthin) for use in a range of food products and cosmetics, such as vitamin supplements and health 
products and as feed additives for poultry, livestock, fish and crustaceans [30]. 
Microalgae are a rich source of carotenoids [123–125]. Marine microalgae contain up to 0.2% of 
carotenoids. For this reason, they are not only a valuable source of the purified compounds, but also 
potential functional foods that are at present being studied as chemopreventive agents against 
inflammation and cancer [44,126]. 
The main sources of carotenoids are microalgae that belong to the Chlorophyceae family. 
Dunaliella has the highest content of β-carotene (up to 1% dry weight), and Haematococcus pluvialis 
accumulates the highest levels of xanthophylls (astaxanthin). Microlgae synthesize all xanthophylls 
produced by higher plants (violaxanthin, anteraxanthin, zeaxanthin, neoxanthin and lutein), and they 
can also produce others, such as astaxanthin, loroxanthin and caraxanthin [123]. Fucoxanthin, 
diatoxanthin and diadinoxanthin are produced by brown algae or diatoms [127].  
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3.2.1.1. β-Carotene 
The main microalgae used as source of β-carotene (β,β-carotene) are Dunaliella and  
Haematococcus [38]. Dunaliella salina is grown on large outdoor terrains in some countries like Israel, 
producing large amounts of β-carotene for the market [30]. The biomass of some marine Tetraselmis 
and Pyramimonas strains is also used for fish food additives [128]. 
Fruits and vegetables are the main sources for human dietary carotenoids. β-Carotene is the most 
prominent member of the group of carotenoids that is present in the human diet, and it is an important 
source of vitamin A [129]. Some of the antioxidant and anticancer effects of β-carotene are related to 
its processing to retinol. The retinoids are a class of natural and synthetic molecules structurally related 
to vitamin A [130]. These compounds have a broad spectrum of biological activities and can influence 
reproduction, embryogenesis, growth, differentiation, proliferation, apoptosis, vision, bone formation, 
metabolism, hematopoiesis and immunological processes [131]. Vitamin A and retinoids can influence 
oncogenesis and prevent several types of cancer [132]. The β-carotene rich marine microalga 
Dunaliella bardawil has been used as source of retinol in a rat diet [133]. Both dried Dunaliella 
bardawil and an oil extract of the alga were shown to satisfy the total requirement of retinol in rats. 
The anti-inflammatory activity of β-carotene has been shown in many in vitro and in vivo  
models [134,135], and it is applicable in IBD. Although β-carotene was reported to have no effect on 
inflammatory markers, it altered their proteomic response in Caco-2 intestinal epithelial cells and 
could act preventively on intestinal inflammatory diseases such as CD and UC [136]. Recently, it was 
shown that β-carotene treatment ameliorated the severity of UC in a DSS mouse model [137]. The 
effect was related to modulation of various molecular targets, such as NF-κB, COX-2, matrix 
metalloproteinase 9 (MMP-9), among others, and it involved a decrease of both local and systemic 
damage. Dunaliella bardawil was used to pre-feed rats, and this treatment protected against acetic-acid 
induced bowel inflammation [138]. It is worth noting that patients affected by early-stage IBD had low 
serum concentrations of micronutrients including Se and β-carotene [139]. Similarly low levels of  
β-carotene were found in CD [140,141] and in UC and CD subjects [142,143]. These results suggest 
that UC and CD patients could benefit from the consumption of natural Dunaliella-derived β-carotene. 
Several in vitro studies showed that β-carotene displayed growth inhibitory and pro-apoctotic 
effects on human colon cancer cell lines [144]. Animal models of colon carcinogenesis have shown 
that dietary supplementation of β-carotene had anticancer effects on AOM-induced colon carcinogenesis 
in rats [145]. In addition, both β-carotene and retinoic acid decreased migration, invasion and MMP 
expression in LoVo colon carcinoma cells [146]. MMPs are required for invasion of tumor cells into  
a new tissue. Despite the prevailing experimental evidence for a beneficial role of β-carotene, there are 
some controversial results, such a study with male F344 rats that investigated the role of β-carotene 
and lutein in CRC [147]. Data showed that the chemopreventive activity of these compounds against 
colon carcinogenesis depended on the dose level, with the highest dose even being harmful. 
Consumption of β-carotene has been inversely correlated with CRC risk. Epidemiologic studies 
indicate that an increased intake of fruits and vegetables that contain carotenoids, such as β-carotene 
and retinol, is associated with a decreased risk of many types of cancer and degenerative diseases 
probably due to their antioxidant and anti-inflammatory activities [148]. This association was not found 
for carotenoids in some studies. For example, in a pooled analysis of 11 cohort studies (North America 
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and Europe) the data did not suggest that dietary carotenoids played an important role in the etiology 
of CRC [149]. The Fukoaka CRC study in Japan showed that retinol intake was inversely associated 
with cancer risk, but this association was not shown for dietary β-carotene [150]. The association of 
prediagnostic plasma concentration and dietary comsumption of carotenoids and vitamins A, C and D 
with the risk of CRC was examined in a case-control study nested within the European Prospective 
Investigation into Cancer and Nutrition study [151]. An association between higher prediagnostic 
plasma retinol concentration and lower risk of CRC was found. Although results also showed an 
inverse association for dietary β-carotene and vitamins A, C and D with CRC, this was not found for 
plasma concentrations, suggesting that the possible inverse association between fruit and vegetable 
consumption and CRC may therefore not be based on these compounds. On the other hand, the findings 
that several retinoic acid metabolizing enzymes are significantly overexpressed in CRC [152], and that 
enzymes of the retinoid acid biosynthetic pathway are dysregulated [153], highlight the importance  
of retinoic acid in CRC. 
Nevertheless, an attenuation of the CRC risk was associated with increased dietary β-carotene in 
many other studies. A study in Israel showed an inverse association of most carotenoids, including  
β-carotene, lutein and zeaxanthin, with CRC risk. Smoking attenuated this protective effect [154]. In 
another study, a relatively high serum level of β-carotene was inversely associated with the risk of 
CRC in postmenopausal women [155]. Similarly, a study in a cohort of male health professionals in 
the USA found that a diet high in carotenoids was associated with a reduced risk of colorectal 
adenomas (inverse associations for β-carotene and lutein/zeaxanthin) [156]. Most recently, a study of 
the association between dietary carotenoid intake and CRC risk in Chinese adults showed inverse 
associations between β-carotene intake and CRC risk only in males [157]. 
In summary, there is an important potential for Dunaliella biomass or Dunaliella-derived  
β-carotene in UC and CD. It also seems that β-carotene may be important as source of retinol in CRC, 
although more information relative to retinoic acid metabolism is necessary. 
3.2.1.2. Astaxanthin 
The ketocarotenoid astaxanthin (3,3′-dihydroxy-β,β-carotene-4,4′-dione) is a red pigment common 
to many marine animals contributing to the reddish pink color of their flesh [158]. The main sources of 
astaxanthin are Haematococcus pluvialis, Chlorella zofigiensis and Chlorococcum sp. [39,40]. The 
amounts collected by the green alga Haematococcus pluvialis exceed any other reported source, 
corresponding to up to 4%–5% of dry weight. The use of Chlorella zofigiensis as an alternative to 
Haematococcus pluvialis for production of astaxanthin is reviewed in Liu et al. [40]. Mammals lack 
the ability to synthesize astaxanthin or to convert dietary astaxanthin into vitamin A; unlike β-carotene, 
astaxanthin has no pro-vitamin A activity [159]. 
There has been growing interest in the use of astaxanthin as a food-coloring agent, natural feed 
additive for the poultry industry and for aquaculture, especially as a pigment for fish feeds in the 
culture of salmon and trout. There have also been reports concerning its application in medicine due to 
its potent bioactivities including its antioxidative, anticancer, antidiabetic and anti-inflammatory 
activities, gastro-, hepato-, neuro-, cardiovascular, ocular and skin-protective effects and other  
actions [39,160]. 
Mar. Drugs 2015, 13 6164 
 
 
Asthaxanthin has been used for preventing inflammatory processes, such as colitis, and some types 
of cancer, including CRC, in cellular and animal models. The anti-inflammatory activity of astaxanthin 
in cellular models is due to supression of iNOS expression [161]. The inhibitory effect of astaxanthin 
on the production of NO has important implications for the treatment of IBD. 
Astaxanthin could inhibit the growth of human CRC cells, including HCT-116, HT-29, LS-174, 
WiDr and SW-480 [126]. A significant decrease in the incidence of induced CRC in rats fed with 
astaxanthin versus animals administered only the carcinogen was found [162]. The inhibitory effect of 
astaxanthin against chemically induced colonic pre-neoplasic progression has also been demonstrated 
in a dimethylhydrazine (DMH)-induced rat colon carcinogenesis model [163]. In the same line, 
astaxanthin induced apoptosis in DMH-induced rat colon carcinogenesis through the regulated 
expressions of COX-2, NF-κB, MMP-2 and 9, proliferating cell nuclear antigen (PCNA) and 
extracellular signal-regulated kinase (ERK-2) [164]. Dietary astaxanthin ameliorated the colonic 
inflammation induced by DSS in mice by reducing the proinflammatory factors TNF-α, IL-1β, COX-2 
and NF-κB [165]. In the same study, it was shown to reduce AOM/DSS-induced colorectal 
carcinogenesis, partly due to its anti-inflammatory effects as well as to suppression of proliferation and 
induction of apoptosis.  
There are no clinic trials with astaxanthin and IBD or CRC patients. Nevertheless, several studies in 
humans show beneficial effects for astaxanthin related to its antioxidant activity, such as 
prophylaxis/regression of stomach ulcers caused by Helicobacter pylorii infection [166]. In the same 
line, astaxanthin enhanced both cell-mediated and humoral immune responses in young healthy 
females, in a randomized double-blind, placebo-controlled study [167], and it also improved facial 
elasticity in a model of proaged skin in humans [168]. These studies did not reveal any harmful effect. 
3.2.1.3. Lutein 
Lutein (3R,3′R,6′R-βε-carotene-3,3′-diol) is a yellow oxycarotenoid or xanthophyll containing  
two cyclic end groups (one beta and one epsilon-ionone ring). In green microalgae, lutein protects cells 
from ROS damage under stress conditions. Lutein has been widely used as a feed additive and a food 
coloration agent in industry [169], and it may also protect against age-related macular degeneration in 
humans [170]. The role of the dietary xanthophyll carotenoids, lutein and zeaxanthin has been 
extensively studied in adult onset macular degeneration. At present, lutein is mainly produced from the 
flowers of marigold, but the content is low, about 0.3% dry biomass [171]. This has led to considerable 
interest in other sources of lutein, notably microalgae, as they have a high lutein content  
(0.5%–1.2% dry weight) [169]. A Dunaliella salina strain developed for β-carotene production has 
been shown to be a potential producer of lutein under environmental stress conditions [41]. Chlorella 
sorokiniana is also a good source for lutein, and the yield can be improved by managing several 
nutritional and environmental factors and by random mutagenesis [44]. Chlorella prothecoides has 
also been proposed as a potential source of lutein [43].  
Many of the beneficial effects of lutein are linked to its ability to quench singlet oxygen, and it is 
also an excellent free radical scavenger [172]. This antioxidant activity is thought to be responsible for 
reducing injury due to oxidative and inflammatory processes in cells and tissues [48,173]. An in vitro 
study showed a cytoprotective effect of lutein on the human colon adenocarcinoma cell line HT-29 
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against deoxynivalenol-induced oxidative stress and inflammation, by maintenance of glutathione 
levels, inhibition of nuclear migration of NF-κB, downregulation of COX-2 expression and prevention 
of apoptosis [174]. 
Lutein also has anticancer activity [175]. As previously mentioned for β-carotene, a study with male 
F344 showed that the chemopreventive activity of both carotenoid compounds against colon 
carcinogenesis was dependent on the doses [147]. Extracts from Chlorella vulgaris, whose main 
constituent was lutein, displayed anti-proliferative effects on a human colon cancer cell line  
(HCT-116) [176]. More recently, lutein showed chemoprotective activity against CRC induced by 
DMH in the rat by modulating the proliferative activity of K-ras, protein kinase B (PKB) and  
β-catenin [177]. 
3.2.1.4. Violaxanthin 
Violaxanthin (5,6,5′,6′-diepoxy-5,6,5′,6′-tetrahydro-β,β-carotene-3,3′-diol) is a natural xanthophyll 
pigment with an orange color found in a variety of plants, macro- and micro-algae. This product has been 
isolated from several microalgae including Dunaliella tertiolecta [44] and Chlorella ellipsoidea [45].  
Violaxanthin had antiproliferative and pro-apoptotic activity against human cancer cell lines [44]. 
Extracts from the marine microalga Chlorella ellipsoidea, whose main constituent was violaxanthin, 
displayed anti-proliferative effects on a human colon cancer cell line (HCT-116) by inducing  
apoptosis [176]. In addition, violaxanthin isolated from Chlorella ellipsoidea showed antiinflamatory 
activity when it was tested on LPS-stimulated RAW 264.7 mouse macrophages, by inhibiting NF-κB 
activation and NO and prostaglandin E2 (PGE2) production [45]. The anti-inflammatory and 
anticancer activities of violaxanthin may be of interest in IBD and CRC. 
3.2.1.5. Zeaxanthin 
Zeaxanthin (β,β-carotene-3,3′-diol) together with lutein accumulate in the central retina. 
Epidemiologic studies suggest that insufficient dietary lutein and zeaxanthin intake or lower serum 
zeaxanthin levels are associated with increased risk for age-related macular degeneration [178]. Zeaxanthin 
has been obtained from the cyanobacterium Synechocystis sp. and Microcystis aeruginosa [46,179], 
Nannochloropsis oculata [180] and Chlorella saccharophila [47]. 
Similarly to lutein, zeaxanthin showed antioxidant and anti-inflammatory properties [181].  
Most studies were related to the protective effect of lutein and zeaxanthin against the development of 
macular degeneration. 
A study investigating the association between serum concentrations of carotenoids and the presence 
of colorectal polyps and cancers in Japanese people showed that high serum zeaxanthin was associated 
in males with decreased rates of polyps and cancer, and in females, with cancer development [182]. 
3.2.1.6. Fucoxanthin 
The xanthophyll fucoxanthin [(3S,3′S,5R,5′R,6S,6′R,8′R)-3,5′-dihydroxy-8-oxo-6′,7′-didehydro-
5,5′,6,6′,7,8-hexahydro-5,6-epoxy-β,β-caroten-3′-yl acetate] is a marine carotenoid found in numerous 
classes of microalgae (bacillariophytes, bolidophytes, chrysophytes, silicoflagellates, pinguiophytes) 
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and brown macroalgae (phaeophytes) [183,184]. Diatoms exhibit a characteristic golden-brown color 
due to a high amount of the xanthophyll fucoxanthin that plays a major role in the light-harvesting 
complex of photosystems. The diatom Phaeodactylum tricornutum [48] has been proposed as a 
commercial source for fucoxanthin, with a production higher than 1.5% dry weight. A similar amount 
of fucoxanthin was produced by the Haptophyta Isochrysis sp. [49].  
The increasing interest for this carotenoid is mainly due to its anti-obesity effect, primarily detected 
by murine studies, which showed that fucoxanthin induced the expression of uncoupling protein-1, 
thus promoting the oxidation of fatty acids and heat production [185]. In addition, fucoxanthin has 
shown a great antioxidant activity, anti-cancer, anti-diabetic and anti-photoaging properties [183]. 
Fucoxanthin displayed anticancer activity in several experimental models against a variety of cancer 
types [186]. With respect to CRC, fucoxanthin has shown cytotoxic activity against several human 
colon cancer cell lines [187,188], inducing apoptosis and cell cycle arrest. The effect of fucoxanthin on 
cell viability of colon cancer cell lines (Caco-2, HT-29, and DLD-1) was higher than the effect of other 
carotenoids, such as β-carotene and astaxanthin [187]. 
3.2.2. Fatty Acids 
Over the last decades, microalgal lipids have gained significant importance, not only due to their 
feedstock for biofuels production, but also as important biological molecules for the treatment of 
inflammatory pathologies such as IBD, atherosclerosis, Parkinson’s and Alzheimer’s diseases, 
psoriasis or cancer [189]. Many of these compounds are long chain fatty acids that can be either 
saturated or unsaturated, polyunsaturated fatty acids (PUFAs) being the most studied for their 
pharmacological potential. These fatty acids have been found to have many benefits on human health, 
including protection against CRC [190–192]. Fish oils are the major source of n-3 PUFAs due to their 
high levels of EPA, docosahexaenic acid (DHA) and docosapentaenoic acid (DPA); however, their 
clinical use is often limited by their unpleasant fishy taste and their adverse effects [193] as well as 
their frequent contamination with heavy metals or the decline of global fish stocks [35]. Therefore, in 
recent years, microalgae have become a good alternative source of PUFAs such as EPA, DHA and 
DPA. Although these organisms have an elevated content in these compounds, bioengineering could 
produce huge amounts for pharmaceutical use. The most representative species of microalgae rich in 
fatty acids are Tetraselmis sp. and Nannochloropsis oculata [50–54]. 
A multitude of publications have revealed the therapeutic role of fatty acids in different types of 
inflammatory pathologies, such as Alzheimer’s disease [194], rheumatoid arthritis, lupus [195] or  
IBD [196]. An in vitro study on the colon adenocarcinoma cell line Caco-2 expressing GPR120  
(G-protein coupled receptor with anti-inflammatory signaling properties after binding n-3 PUFAs) 
evidenced that EPA and DHA inhibited NF-κB activity and IL-1β secretion by activating ERK1/2 
MAP kinase [50,197]. In the same line, DHA and DPAn-6 algal oils have been demonstrated to reduce  
TNF-α and IL-1β secretion as well as downregulate COX-2 expression and the subsequent PGE2 
production in a human peripheral mononuclear cell line. These algal oils also reduced paw edema to an 
extent similar to indomethacin in rats, suggesting their anti-inflammatory properties [52]. In vivo 
studies have shown that a diet rich in EPA and DHA, found principally in oily fish, has potent  
anti-angiogenic effects mainly in colon, breast and prostate cancers, inhibiting production of many 
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important angiogenic mediators such as vascular endothelial growth factor (VEGF), platelet-derived 
growth factor (PDGF), platelet-derived endothelial cell growth factor (PDECGF), COX-2, PGE2,  
NO, NF-κB, MMPs and β-catenin [54]. In this respect, van Beelen et al. [198] demonstrated the 
chemopreventive effects of an n-3 PUFA-rich microalgal oil diet in a similar extent that a fish oil-rich 
diet on AOM-induced colonic aberrant crypt foci (ACF) in mice, in comparison with corn oil diet. 
Thus, microalgal oil proved to be a good alternative to fish oil regarding protection against CRC. As 
mentioned above, EPA and DHA are n-3 fatty acids found mainly in fish oil [199,200] but also in  
microalgae [51,53]. Given EPA and DHA are not synthetized by animal tissues, they must be ingested 
with the diet. These fatty acids have been found to decrease vascular cell adhesion molecule 1  
(VCAM-1), toll-like receptor 4 (TLR4), COX-2 and vascular endothelial growth factor receptor 2 
(VEGFR2) expression as well as the production of other inflammatory mediators such as IL-6, IL-8, 
granulocyte macrophage colony-stimulating factor (GM-CSF), PGE2 and leukotriene B4 (LTB4) in  
IL-1β-induced human intestinal microvascular endothelial cells (HIMEC). Similarly, dietary 
intervention with fish oil rich in EPA and DHA significantly decreased colon production of PGE2 and 
LTB4, endothelial VCAM-1 and VEGFR2 in rats with colitis [201]. 
The first anti-inflammatory action of marine n-3 PUFAs found in humans was a reduction in 
generation of arachidonic acid (AA)-derived eicosanoids like PGE2 and LTB4 [202]. This effect 
correlated with a decrease in AA content, detected after a long period of intake of marine n-3 PUFAs [203]. 
EPA acts as an inhibitor of AA metabolism through COX and lipoxygenase (LOX) signaling 
pathways. In addition, EPA is a substrate for COX and LOX enzymes. 
 
Figure 2. Resolution of inflammatory process after an infection or tissue damage. 
Biosynthetic pathways and actions of lipid mediators derived from arachidonic acid (AA), 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). 
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In animal tissues, other families of lipid mediators derived from EPA and DHA are resolvins, 
protectins, lipoxins and maresins. Generically, all of them are oxidative PUFAs called oxylipins 
(OXLs). These OXLs are synthetized via COX and LOX and they are found to have anti-inflammatory 
and inflammation pro-resolving effects [204]. The resolution of inflammation is the key to restore 
tissue homeostasis and limit damage. In fact, Serhan et al. [205] demonstrated, for the first time,  
that this group of animal OXLs are synthetized during the inflammatory process and are able to 
promote the resolution of acute phase of inflammation. The main OXLs synthesis pathways in animals 
are shown in Figure 2. In microalgae, n-3 fatty acids-derived OXLs are produced from linoleic and  
α-linolenic acids and they have also shown a potent anti-inflammatory activity through decrease of 
inflammatory cytokines levels such as TNF-α [206] or amelioration of 2,4,6-trinitrobenzenesulfonic 
acid (TNBS)-induced colitis in rats [207]. In summary, the consumption of n-3 fatty acids such as EPA 
or DHA could have a beneficial effect in the resolution of inflammatory processes and thus prevent 
their progression to cancer.  
3.2.3. Glycolipids 
This type of complex lipids is widespread in nature especially in plants and bacteria, where they are 
mainly located in the thylakoid membranes of chloroplasts and cyanobacteria. Their general structure 
consists of a carbohydrate moiety that is beta-monogalactosyldiacylglycerol (MGDG) and 
digalactosyldiacylglycerol (DGDG) or alpha-linked sulfo-quinovosyl-acyl-glycerol (SQAG) to the  
sn-3 position of glycerol, which is acylated at the residual hydroxyls by fatty acids of different lengths 
and degrees of unsaturation [208]. They are present on the outer surface of eukaryotic cells membranes 
for cellular recognition as well as for providing energy or stability to the membrane [209]. The first 
evidence of the presence of glycolipids in microalgae was described in Gymnodinium, a genus of 
dinoflagellates (Dinophyceae class). The content of glycolipids in Gymnodinium mikimotoi was 17% 
of MGDG and DGDG, while in Gymnodinium sp. the proportion was double. Both compounds were 
shown to have hemolytic actions [210]. Several papers have revealed the high content of glycolipids in 
microalgae. In this regard, a study with the microalga Pavlova lutheri revealed that EPA was 
especially concentrated in MGDG (45%) as well as that DHA was dispersed within triacylglycerol 
(TAG) (27%), diacilphosphoglycerol (DPG) (22%) and betaine lipids (21%) [211]. Microalgae are rich 
in other chemical features of TAG. Xu et al. [212] performed a global characterization of different 
glycolipids from a marine diatom Stephanodiscus sp. In this study, 16 MGDGs, nine DGDGs,  
23 SQDGs and eight phosphatidylglycerols (PGs) were identified. All of these lipids have shown a 
high potential as an alternative fuel source [213,214], but they could have an important role in 
pathologies related with NO signaling pathways, such as inflammatory diseases. In this line, 
methanolic extracts of Tetraselmis chui showed NO inhibitory activity on LPS-induced NO production in 
RAW264.7 macrophage cells [215]. A similar extract of the marine macroalga Palmaria palmata 
inhibited LPS-induced NO production in the same cell line through down-regulation of iNOS [216].  
It is noteworthy that glycolipids from plants have shown anticancer activities in CRC. A glycolipid 
fraction from spinach containing mainly MGMG, MGDG, DGDG and SQDG inhibited DNA 
polymerase activity [217] and cell growth in human gastric cancer cells, as well as suppressed tumor 
growth in a tumor graft study [55]. In this line, the same glycolipid fraction caused a decrease in  
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a solid adenocarcinoma (colon-26) tumor growth in mice without any side effects (loss of body weight 
or organ failure) by inhibition of angiogenesis and the expression of cell proliferation marker proteins 
such as Ki-67, PCNA and cyclin E in the tumor tissue [58,59]. Moreover, liposomes carrying  
surface-bound sialyl Lewis X (SLX) and containing MGDG (SLX-Lipo-MGDG) in nude mice bearing 
HT-29 human colon adenocarcinoma tumors showed a stronger and more promising suppression of 
solid tumor than MGDG alone [56]. In the same line, DGDG and SQDG from the Brown alga 
Sargassum horneri caused an apoptosis induction by fragmentation of DNA in Caco-2 colon cells [57]. 
All these studies of different glycolipids from plants or macroalgae demonstrate the potential of 
glycolipids as useful tools against CRC development. 
More recently, an in vivo study in a young man demonstrated that the oils extracted from the 
microalgae Nannochloropsis oculata (rich in EPA conjugated to phospholipids and glycolipids but no 
DHA) might improve the bioavailable of EPA and DHA in human plasma in comparison with the oil 
from krill (rich in EPA and DHA). Moreover, this difference may be related to the different chemical 
constituents, especially the presence of glycolipids [218]. Glycolipids have been demonstrated to have 
bioactive effects in inflammatory processes involved with NO, but more studies are necessary to 
investigate this important role in inflammatory pathologies. 
3.2.4. Polysaccharides 
Algae (micro- and macroalgae) produce polysaccharides with applications in the pharmaceutical 
and biomedical industries due to their biological activities: anti-inflamatory, antioxidant, antiviral, 
anticoagulant, anticancer and inmunomodulating [219]. However, the use of polysaccharides is 
restricted for various reasons, including a lack of simple methods for isolating them from extracts. 
Despite the fact that several methods for isolation of seaweed polysaccharides have been reported, all 
of them are rather work demanding and time consuming. In this respect, several microalgae secrete 
polysaccharides into the culture medium and these polymers are easily extracted [220]. 
Microalgae are excellent sources of polysaccharides whose beneficial activities have been 
demonstrated in various kinds of cell lines and animal models. These include polysaccharides from 
diatoms, chlorophytes, prasinophytes, haptophytes, rhodophytes, dinoflagellates and cyanobacteria [219]. 
There is a big amount of reports covering the antioxidant, anti-inflammatory, anticancer and 
immunomodulatory activities of polysaccharides derived from microalgae; nevertheless, there is little 
information on the effect of these compounds on IBD and CRC. The main results are summarized below.  
Microalgae polysaccharides are potent antioxidant. For example, polysaccharides extracted from 
Isocrysis galbana showed scavenging activity against superoxide and hydroxyl radicals [221]. 
Similarly, polysaccharides from Pavlova viridis and Sarcinochrysis marina Geitler and their 
degradation fragments showed antioxidant activity using 1,1-diphenyl-2-picrylhydrazyl (DPPH), 
hydroxyl-radical (OH) scavenging, lipid peroxidation inhibition and the mouse red blood cells (RBCs) 
hemolysis assay [222].  
Pectic polysaccharides extracted from the plant Rauwolfia verticillata (Lour.) Baill.var.hainanensis 
Tsiang showed a potent anti-inflammatory effect on an experimental murine colitis model induced by 
DSS, decreasing the level of proinflammatory molecules such as activated NF-κB, TNF-α and IL-17 [223]. 
In the same line, dietary non-digestible polysaccharides had similar effects in the same experimental 
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DSS mice model [224]. The effect could be related to restoring the balance between intestinal 
microbiota and mucosal immune responses. Their verified antioxidant and anti-inflammatory activities 
make these compounds very promising tools in IBD. 
Microalgae polysaccharides have shown anticancer activity in several models, including CRC. An 
extracellular polysaccharide, GA3P (D-galactan sulfate, associated with L-(+)-lactic acid), synthesized 
by the toxic marine dinoflagellate Gymnodinium sp. A3, proved to be a potent inhibitor of DNA topo I 
and topo II irrespective of the presence or absence of the lactate group [225]. It inhibited growth of 
different cancer cell lines, as well as several colon cancer cell lines (HCC2998, KM-12, HT-29, WiDr, 
HCT-15 and HCT-116). 
On the other hand, polysaccharides extracted from the microalgae Aphanizomenon flos-aquae, 
Chlorella pyrenoidosa and Spirulina platensis showed immunoestimulatory activity in THP-1 human 
monocytic cells [226]. The activity corresponded to high molecular weight polysaccharides that were 
named Immulina (for Spirulina platensis), Immunon (for Aphanizomenon flos-aquae) and Immurella 
(for Chlorella pyrenoidosa). Mice that consumed an extract containing Immulina displayed enhanced 
innate immune activity [227]. This immunoestimulatory effect has also been shown in other animal 
species and in humans [228]. These findings suggest the potential of these compounds as agents for 
immunotherapy in the treatment of cancer.  
3.2.5. Proteins and Peptides 
Due to their high protein content, microalgae are considered potential cell factories for both 
alimentary protein sources and for the production of therapeutic peptides and proteins [229]. Proteins 
from marine sources have many important and exclusive properties such as their film and foaming 
capacity, gel forming ability and antimicrobial activity [230]. Several therapeutic bioactivities have 
been described for phycobiliproteins from cyanobacteria and red algae, such as Spirulina platensis and 
Porphyridium sp.: hepatoprotective, anti-inflammatory, immunomodulating, antioxidant and anticancer 
effects [67,68]. For example, the phycobiliprotein C-phycocyanin isolated from Spirulina platensis 
caused the release of cytrochome C from mitochondria and caspase-dependent induction of apoptosis 
in HeLa cells [231]. In addition, C-phycocyanin mediated mitochondrial-dependent apoptosis in the  
DMH-induced rat model of colon carcinogenesis [232]. 
Peptides from microalgae also have interesting biological activities, especially anti-inflammatory [233] 
and anticancer activities [68,234]. A polypeptide from Chlorella pyrenoidosa has shown antitumor 
activity [69], and antihypertensive peptides have been isolated from Chlorella vulgaris and Spirulina 
platensis [235]. Cyanobacterial peptides with antitumoral activity include Symplocamide A from 
Symploca sp. [236], Somocystinamide A from Lyngbya majuscule [237], Apratoxin D from Lyngbya 
majuscula and Lyngbya sordida [238], Dragonamides C and D from Lyngbya polychroa [239] and 
Mitsoamide from Geitlerinema sp. [240]. 
With respect to microalgae-derived peptides, there are several studies in models related to CRC. 
Nostoc sp. produces the depsipeptides cryptophycins [241]. A synthetic analog of cryptophycin 
showed antiproliferative activity against HCT-116 human colon adenocarcinoma cells, causing inhibition 
of both DNA and RNA synthesis and subsequent G2/M arrest [242]. Desmethoxymajusculamide C 
(DMMC), a cyclic depsipeptide from the cyanobacterium Lyngbya majuscula exhibited antitumor 
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activity against the human colon carcinoma cell line HCT-116 [243]; this effect was related to the 
disruption of microfilament networks. In addition, the same study showed that DMMC demonstrated 
efficacy on HCT-116 bearing SCID mice treated with 0.62 mg/kg daily for 5 days. Symplostatin 
isolated from the marine cyanobacterium Symploca hydnoides had antitumor effects in a murine solid 
tumor model, murine colon adenocarcinoma 38, maintained and tested in C57B1/6 mice [244]. Two 
peptidic proteasome inhibitors, carmaphycin A and B, exhibited strong cytotoxicity against lung and 
colon cancer cell lines [245]. In the same line, cyclic decapeptides isolated from Anabaena 
minutissima (UTEX 1613) exhibited antiproliferative activity against the HT-29 human colon cancer cell 
line [246]. Pitipeptolides, cyclic depsipeptides isolated from the marine cyanobacterium Lyngbya 
majuscule [247] and Grassypeptolide from Lyngbya confervoides [248], displayed cytotoxic activity 
against HT-29 cells, causing cell cycle arrest and inducing apoptosis. Pitipeptolides, Symplostatin, and 
other peptides that have cytotoxic activity against colon cancer cell lines, are dolastatin analogs  
(see below).  
Dolastatins are microtubule-disrupting agents produced by Lyngbya sp. and Symploca sp. [249]. 
They showed cytotoxic activity on a panel of human ovarian and colon carcinoma cell lines that was 
more potent than paclitaxel or vinblastine [250]. TZT-1027, a dolastatin 10 derivative, had antitumor 
activity against three murine solid tumors; colon 26 adenocarcinoma, B16 melanoma and M5076 
sarcoma [251] and in human tumors xenografted in nude mice from colon (H-110, H-143) [252]. 
Dolastatin 10 was not successful as a single agent in phase II clinical trials, and new more potent 
analogs were produced, such as auristatin PYE [253]. This compound was less effective in vitro than 
dolastatin 10, but it had higher efficacy in two human colon adenocarcinoma models, DLD-1 and 
COLO 205. In addition, auristatin PYE potentiated the activity of cisplatin in a human colon tumor 
xenograft model [254]. A dolastatin obtained not from microalgae but from a marine mollusk 
(Dolastatin 15), along with the COX-2 inhibitor celecoxib, could prevent preneoplastic colonic lesions 
in a DMH-induced rat colon carcinogenesis model, through inhibition of NF-κB and iNOS [70], and  
it had anti-neoplastic effects in the same rat model through regulation of the phosphoinositide  
3 kinase/Akt (PI3K/Akt) pathway [255]. Finally, two peptides produced by Symploca sp., largazole 
(histone deacetylase inhibitor) and dolastatin 10, showed cooperative activity against HT-29 colon 
cancer cells [256]. 
3.2.6. Other Compounds 
Cyanobacteria have been shown to be good producers of bioactive secondary metabolites with 
anticancer activity [257]. Some of them have shown activity against several colon cancer cell lines. 
The calothrixins are quinone-based natural products isolated from Calothrix cyanobacteria that show 
potent antiproliferative properties against several cancer cell lines [258]. Calothrixin B displayed 
antiproliferative activity against HCT-116 colon cancer cell line (IC50 0.32 µM) [72]. Malyngamides 
are small amides produced by marine cyanobacteria; malyngamides isolated from Lyngbya majuscule 
(malyngamide C and 8-epi-malyngamide C) were found to be cytotoxic to HT29 colon cancer cells 
(IC50 5.2 μM and 15.4 μM, respectively) [71]. Merocyclophanes A and B, isolated from a terrestrial 
Nostoc sp. (UIC 10022A), displayed antiproliferative activity against HT-29 cells (IC50 values of  
3.3 and 1.7 µM, respectively) [259]. Hierridin B, a secondary metabolite (polyketide) isolated from  
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the marine cyanobacterium Cyanobium sp. LEGE 06113, tested in a panel of eight human cancer  
cell lines, showed selective cytotoxicity towards HT-29 cells, although with moderate potency  
(IC50 0.1 mM) [260]. 
Other microalgae-derived compounds with therapeutical potential in IBD and CRC, due to their 
antioxidant activity, include tocopherols from Porphydium sp. and Spirulina platensis [70], and 
phenolic compounds (benzoic acid and cinnamic acid derivatives, hydroxybenzldehydes) from 
Spirulina maxima, Chlorella ellipsoidea and Nannochloropsis sp. [73,74]. 
4. Inflammation and Skin Cancer 
4.1. Molecular Pathways of Skin Carcinogenesis 
Skin is considered the largest organ in the body and acts as a physiological barrier that protects us 
from the deleterious effects of solar UV radiation, which is the main cause for skin cancer. This cancer 
is currently the most common type of human cancer worldwide [261]. Of the UV light, which reaches 
the Earth, 5% is UVB while the remaining 95% is UVA. UVB only penetrates into the epidermis and 
can induce a variety of both acute and chronic adverse effects, including skin photoageing, 
inflammation, immunosuppression and direct DNA damage with signature mutations predisposing to 
skin cancers [262]. UVA can penetrate deeper into the underlying dermis and, in comparison to UVB, 
is less damaging, being related to ageing skin events. Moreover, it can damage DNA indirectly through 
the generation of free radical and oxidative injury [263]. 
Exposure to UV radiation is associated with the development of approximately 65% of melanoma 
cases and nearly 90% of non-melanoma skin cancers (NMSC) [264]. NMSC is the most common form 
of cancer diagnosed in the white-skinned population. Its incidence has increased dramatically 
worldwide, developing even in younger age groups. The two major types of NMSC comprise basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC), and account for approximately 80% and 20% 
of all skin cancers, respectively. Almost all cases of NMSC arise on sun-exposed areas of skin, like the 
face, ears, neck and back of the hands, implicating chronic exposure to solar UV radiation as the major 
etiologic factor [265]. BCC is the most common easily treated form of skin cancer in Europe and the 
United States with an estimated average annual incidence of 100 per 100,000 inhabitants [266]. The 
risk of BCC seems to be similar for young males and females, but after the age of 45 years, men are 
twice more likely to present BCC than women. BCC tumors grow slowly (months to years), are locally 
invasive and rarely metastasize (0.003%–0.55%) or cause death [267]. 
SCC, the second most common type of skin cancer, is a tumor with local destructive properties  
and men have a three times higher risk than women at all ages. This cancer mainly occurs in the  
centro-facial region in people with fair skin, blond or red hair and blue or green eyes. In contrast to 
BCC, SCC tends to grow more rapidly (weeks to months) and if untreated, it can become locally 
invasive, leading to metastases in about 5% of all cases [268]. The highest risk factor is the presence of 
actinic keratosis (AK), which can progress to SCC in 5%–10% of cases. [269]. AKs develop in  
sun-exposed areas, including the face, forehead, scalp, neck and dorsum of the hands. AKs are small 
lesions (3–6 mm) characterized by the formation of rough or scaly macules, papules, or plaques of 
reddish/brown-color on an erythematous base [270]. They are characterized by dysplastic keratinocyte 
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lesions confined to the basal epidermal layer of the skin. If untreated, up to 10% of AKs can undergo 
malignant transformation and progress to SCC. In rarer instances, AKs may also turn into BCC [271].  
On the other hand, AKs have also been shown to regress spontaneously [272]. Currently, authorities 
debate whether AK should be considered as SCC in situ or as a premalignant precursor to invasive 
SCC. However, it is clear that they represent an intermediate stage in a multistep evolution of SCC. 
The risk of transformation of AK to SCC (invasive or in situ) increases with rapid enlargement, 
bleeding, erythema, ulceration, pain, inflammation and diameter greater than 1 cm, as well as in 
immunocompromised patients [273]. Since it is not possible to predict whether a given AK will 
regress, persist, or develop into SCC, early treatment of AK is recommended. The current 
interventions available can be broadly grouped into two categories: individual lesion-based treatments, 
including curettage and cryotherapy with liquid nitrogen, and field-directed therapies, such as 
photodynamic therapy and topical therapies (5-fluorouracil, diclofenac, imiquimod or ingenol 
mebutate), targeted at multiple lesions over a large area. However, topical therapies have long 
treatment durations, typically up to 16 weeks, and can elicit local skin responses, as erythema, 
ulcerations, and crusting [274]. 
Skin inflammation can be caused by mechanical injuries, chemical or biological agents, 
immunologic disorders and physical agents, such as UV radiation. Epidemiological studies and 
numerous animal models, such as those of UV-induced or chemically induced skin carcinogenesis, 
provide strong evidence for a critical link between the inflammatory microenvironment and the 
development and progression of cancer [275]. The connection between inflammation and skin cancer 
can be viewed as consisting of two pathways: the intrinsic and extrinsic pathways. In the intrinsic 
pathway, genetic mutations by UV-induced DNA damage can lead to inactivation of tumor suppressor 
genes, such as p53, p16 INK4a and p14ARF [276]or activation of oncogenes, including RAS 
oncogenes (HRAS, KRAS and NRAS) and BRAF [277]. In the extrinsic pathway, exposure of skin to 
chemical, physical or biological agents induces an inflammatory response that includes vasodilation, 
microvascular structural changes and escape of plasma proteins from the bloodstream, and 
transendothelial migration of leukocytes at the site of tissue injury [278]. Neutrophilic infiltration 
induces ROS and RNS production, which can directly damage chromatin and promote DNA 
mutagenesis or initiate intercellular transduction pathways leading to inflammation and tumor 
formation [279].  
The two pathways converge, resulting in the stimulation of intracellular signal transduction 
pathways, including mitogen-activated protein kinases (MAPK), PI3K/Akt and Janus kinase/signal 
transducers and activators of transcription (JAK/STAT). Subsequently, several transcription factors are 
activated, such as NF-κB, STAT3 and hypoxia-inducible factor-1 alpha (HIF-1α). These transcription 
factors coordinate the production of numerous inflammatory mediators, such as cytokines, chemokines 
and surface adhesion molecules, as well as the synthesis of COX-2 or iNOS [280]. Excessive production 
of proinflammatory factors leads to chronic inflammation, which in turn may increase the risk of 
tumorigenesis. Therefore, pharmacological control of the inflammatory response of the skin to solar 
radiation may be beneficial in decreasing the incidence of skin cancer. 
MAPKs regulate the actions of a variety of downstream transcription factors involved in cancer 
development [281,282]. Previous papers have demonstrated a critical role for the MAPK pathway in 
UVB-induced skin damage and skin cancer. In the human keratinocyte HaCaT cell line, UVB 
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exposure induced the phosphorylation of ERK, JNK and p38 MAPKs, with the main signaling 
pathways being that activated by UV radiation in these cells [283]. Similarly, in vivo studies have 
shown an enhanced phosphorylation of Erk1/2, p38 and JNK in UVB-induced inflammation in SKH-1 
hairless mice skin [284] as well as in the 9,10-dimethylbenz[a]anthracene (DMBA)/12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation and carcinogenesis model [285]. 
PI3K induces the production of phosphatidylinositol (3,4,5)-trisphosphate, which is responsible for the 
translocation of Akt to the plasma membrane [286]. Activated Akt regulates multiple biological 
processes such as cell survival, proliferation and growth. It has been reported that dysregulation of the 
PI3K/Akt signaling pathway is involved in a number of human diseases, including cancer [287]. In this 
line, the upregulation of PI3K expression and Akt phosphorylation has been demonstrated in different 
animal models of skin tumorigenesis, including UVB-exposed SKH-1 hairless mice [288] and 
chemically induced skin cancer [289]. The JAK/STAT pathway is a signaling pathway employed by a 
large number of cytokines, growth factors and hormones upon binding their specific receptors. 
Receptor-mediated tyrosine phosphorylation of Jak family members activates STAT proteins, which in 
turn directly bind DNA and regulate gene transcription [290]. These proteins and particularly STAT3 
are highly increased in most malignancies and regulate the expression of a wide range of genes that 
contribute to skin carcinogenesis [291].  
As regards to inflammasomes, it has been shown that one of the earliest responses of keratinocytes 
against UV damage is the formation of the inflammasome complex within the cytoplasm. In HaCaT 
keratinocytes, UVB radiation induces rapid ATP release from dying cells into the extracellular space [292], 
leading to activation of NLRP3 and the subsequent increase in IL-1β and IL-18 levels [92]. Prolonged 
IL-1β production after UV-exposure results in tissue damage that can lead to a microenvironment of 
chronic inflammation that promotes cancer development [293]. However, IL-18 represents a  
double-edged sword in cancer, since its activation may stimulate tumor development [294] or 
oppositely, increase anti-tumor immunity and limit tumor growth through the activation of natural killer 
cell responses [295]. The influence of inflammasomes in the carcinoma development has been shown 
to have contrasting roles. A previous study has demonstrated that IL-1 receptor- or caspase-1-deficient 
mice present a reduction in tumor incidence and number in comparison to wild type animals in a model 
of chemically induced skin carcinogenesis. These authors also reported that mice specifically deficient 
in ASC in myeloid cells show a reduced tumor incidence; however, ASC-deficient mice in 
keratinocytes developed more tumors than controls in the same model of skin cancer [296]. Another 
recent paper using ASC or caspase-1 knockout mice supports the function of these proteins in the 
protection against SCC tumorigenesis and progression [297].  
In skin, autophagy is believed to be a form of an endogenous defense mechanism against 
mechanical stresses, chemical or biological agents and UV radiation. Consequently, this process is 
closely related to skin homeostasis and may have a critical role in the development and progression of 
skin diseases [298]. A recent study supporting the tumor-suppressive function for autophagy has 
reported that the activation of this process by serum starvation in SCC cells reduced cell growth and 
senescence [299]. However, other investigations reported the protumoral activity of autophagy in skin 
cancer. In this line, an increased expression of the autophagy marker LC3 has been demonstrated in 
patients with SCC, which was associated with disease progression and prognosis of cancer [300]. 
Interestingly, an in vitro study showed that the inhibition of both Akt signaling and autophagy by the 
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lysosomal inhibitor chloroquine enhanced the susceptibility of metastatic SCC cells to docetaxel-
induced apoptosis [301].  
Sirtuins have an important function in cellular pathways associated with skin structure and function, 
including UV-induced premature skin ageing, inflammation and cancer [302]. In this line, SIRT1 
expression was decreased in human skin keratinocytes after exposure to UV radiation or H2O2. 
Interestingly, treatment with resveratrol, a SIRT1 activator, protected against UV or H2O2-induced 
apoptosis, suggesting that these activators could be used as new skin anti-aging strategies [303]. 
Accumulating evidence indicates that the role of SIRT1 in skin cancer is complex. Recently, a dual role 
of SIRT1 in a model of UVB-induced skin cancer was reported. In this paper, keratinocyte-specific 
heterozygous deletion of SIRT1 enhanced tumorigenesis, whereas homozygous deletion of this gene 
inhibited tumor development [304]. These authors also reported a decrease in SIRT2 protein levels in 
human SCC from sun-exposed areas. In addition, this study confirmed the tumor suppressor effect of 
this sirtuin since SIRT2 knockout mice presented an increased tumor growth in DMBA/TPA-induced 
skin carcinogenesis [305]. However, overexpression of SIRT1 was observed in patients with AK or 
SCC, with no difference between both pathologies, suggesting that this protein may have a function in 
the early stages of skin carcinogenesis [306]. Similarly, a more recent study reported an upregulation 
of gene expression of the seven SIRT family members in epidermal human cells, including HaCaT 
keratinocytes and A431 epidermoid carcinoma cells as well as in human AK or SCC skin biopsies [307].  
4.2. Microalgae as a Source of Biomolecules with Potential in Inflammation and Skin Cancer 
4.2.1. Carotenoids 
4.2.1.1. β-Carotene 
Carotenoids are important compounds with anti-oxidant potential whose structure and physicochemical 
properties could be implicated in their skin protective effects against sunlight damage [308]. Previous 
in vitro studies, investigating the antioxidant potential of β-carotene, have shown that this carotenoid 
reduced the photoinactivation of the enzymes catalase and superoxide dismutase as well as protein  
cross-linking. β-carotene has also been reported to decrease UVA-induced heme oxigenase 1 (HO-1) 
expression in skin fibroblasts [309]. A recent paper evidenced that human dermal fibroblasts incubated 
with an extract enriched in β-carotene and stressed with H2O2 showed an increase in cell viability and a 
reduction of intracellular amount of ROS, membrane lipid peroxidation and DNA damage. Moreover, 
this compound improved mitochondrial functionality, enhancing the basal respiration of mitochondria, 
and promoted the regenerative capacity of cells after exposure to pro-oxidant stimuli [310].  
The anti-inflammatory and photoprotective activity of β-carotene has also been reported in different 
in vivo models. The effects of this compound were evaluated in a mouse ear edema model induced by 
capsaicin or mustard oil, which promoted non-neurogenic edema formation. This study showed that 
the edema, swelling and myeloperoxidase (MPO) activity were gradually decreased after administration 
of β-carotene [311].  
Different papers have reported that supplementation with β-carotene protects the skin against  
UV-induced erythema in humans. Along these lines, increasing doses of β-carotene for 24 weeks 
significantly reduced serum lipid peroxidation after exposure to UV radiation [312]. Another study 
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was conducted in healthy females over the age of 50 years to evaluate the effects of dietary β-carotene 
at two different doses for 90 days on wrinkles, elasticity and UV-induced DNA damage. The results 
showed that only the lowest dose of this carotenoid was able to prevent and repair photoaging [313]. 
As regards skin cancer, a case-control study in NMSC patients reported that the incidence of cancer in 
these patients was inversely related to the level of serum β-carotene and dietary ingestion of this 
carotenoid [314].  
4.2.1.2. Astaxanthin 
The xanthophyll carotenoid astaxanthin has been reported to have a higher preventive effect toward 
photo-oxidative changes than other carotenoids, such as β-carotene or α-tocoferol. Camera et al. [315] 
reported the photoprotective role of astaxanthin on UVA-related damage in human dermal fibroblasts, 
through a reduction in ROS levels and HO-1 expression as well as an increase in antioxidant enzyme 
activities. The skin anti-aging effects of this carotenoid have also been related to the downregulation of 
MMP-1 and skin fibroblast elastase [316]. In addition, astaxanthin decreased the UVB- and UVC-induced 
inflammatory mediator expression, including iNOS, COX-2, macrophage migration inhibitory factor, 
IL-1β and TNF-α in HaCaT keratinocytes as well as inhibited apoptosis by reducing Bax, Bcl-2 and 
caspase-9 [317]. 
An in vivo experiment showed that liposomes containing astaxanthin, topically applied to the dorsal 
skin of hairless mice, prevented UV-induced stratum corneum thickening and inhibited collagen-degrading 
enzymes, thus reducing wrinkle formation. Moreover, this liposomal formulation avoided melanin 
production in the skin after UV exposure [318]. Astaxanthin has also been demonstrated to have 
anticancer activity in vivo. This compound delayed the formation of papillomas and reduced the 
average number of papillomas per mouse in DMBA/TPA-induced skin carcinogenesis model [319].  
In the same line, the effects of astaxanthin and astaxanthin esters from Haematococcus pluvialis on  
UV-DMBA-induced skin cancer in rats have been reported. Interestingly, results from this study 
observed that astaxanthin esters were more potent than astaxanthin in reducing tumor incidence and 
growth, by more strongly inhibiting the accumulation of ROS and tyrosinase enzyme activities. The 
better antitumoral activity of esters could be due to their increased bioavailability [320]. 
Cosmetic effects of astaxanthin have been studied in humans. An open-label non-controlled test 
conducted in healthy females evidenced that oral supplementation of astaxanthin isolated from 
Haematococcus pluvialis combined with its topical application improved skin wrinkle, elasticity and 
moisture content of corneocyte layer after 8 weeks of treatment. Similarly, a randomized double-blind 
placebo controlled study with healthy males demonstrated that the supplementation with this 
carotenoid for 6 weeks also improved the skin condition in males [321]. 
4.2.1.3. Lutein 
The photoprotective effects of lutein, a xanthophyll carotenoid naturally present in microalgae, have 
been previously studied in vitro. Pre-treatment with lutein protected a human keratinocyte cell line 
(CDD 1102 KERTr) and primary human keratinocytes from foreskins against UVB-induced cell 
damage through increased cell viability and proliferation, and reduced apoptosis [322]. 
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Lutein has shown anti-inflammatory effects in a mouse ear edema model induced by capsaicin or 
mustard oil via a marked reduction in swelling and neutrophil infiltration [311]. In relation to cancer, 
this molecule exhibited antitumor-promoting activity on two-stage mouse skin carcinogenesis model, 
through inhibition of peroxynitrite-induced damage [319]. In addition, a photocarcinogenesis model 
conducted in SKH-1 hairless mice fed lutein/zeaxanthin-supplemented diet showed a decreased tumor 
multiplicity and total tumor volume, in comparison with UVB-irradiated control animals fed the 
standard diet [323]. 
In humans, supplementation with capsules rich in lutein and other carotenoids such as β-carotene 
provided moderate protection against erythema induced by UVB in healthy adult volunteers [324]. 
4.2.1.4. Zeaxanthin 
A previous in vitro study supporting the antitumor potential of zeaxanthin reported that this 
compound inhibited PDGF-induced skin fibroblast migration and PDGFR-β and MAPKs 
phosphorylation in a concentration-dependent manner [325]. 
The acute photoprotective capacity of zeaxanthin has been demonstrated in hairless SKH-1 mice fed 
lutein plus zeaxanthin-enriched diet for 2 weeks prior to UVB exposure. Dietary carotenoids reduced 
the edematous cutaneous response and the percentage of PCNA and bromodeoxyuridine positive cells, 
demonstrating that the presence of these antioxidants in the skin may diminish the deleterious oxidant 
effect of irradiation [326]. 
A double-blind, placebo-controlled study in human subjects showed that the combined oral and 
topical administration of lutein and zeaxanthin supplied a higher antioxidant protection, measured by 
changes in lipid peroxidation and photoprotective activity, than administration of these carotenoids 
individually [327]. 
4.2.1.5. Fucoxanthin  
The marine carotenoid fucoxanthin has shown important antioxidant and photoprotective activity in 
different in vitro models. Along these lines, fucoxanthin isolated from Sargassum siliquastrum reduced 
UVB-induced intracellular ROS production, cell damage and apoptosis in human fibroblast in a  
dose-dependent manner [328]. In a similar way, this compound attenuated the levels of ROS in  
H2O2-treated HaCaT keratinocytes as well as quenched the hydroxyl radical generated by the Fenton 
reaction in a cell-free system. Moreover, the protective effects of fucoxanthin against oxidative 
damage were related to inhibition of apoptosis through down-regulation of Bax expression and 
increase of Bcl-2 expression [329]. More recently, Zheng et al. [330] studied the antioxidant  
activity of fucoxanthin in HaCaT cells and showed that this treatment increased the expression of  
glutamate-cysteine ligase catalytic subunit (GCLC) and glutathione synthetase (GSS), two enzymes 
involved in reduced glutathione (GSH) synthesis. The mechanisms underlying these effects were 
related to activation of the transcription factor Nrf2 via PI3K/Akt, which in turn activated the 
transcription of ARE-driven GCLC and GSS genes, leading the synthesis of antioxidant GSH. 
The anti-aging effects of fucoxanthin have also been evaluated in animal models. Topical pre-treatment 
with fucoxanthin from Undaria pinnatifida for 10 weeks tended to diminish the number of wrinkles in 
UVB-irradiated chronically dorsal skin of hairless mice. This pigment reduced UVB-induced 
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epidermal hypertrophy as well as VEGF and MMP-13 expression in the epidermis, which are known 
to induce angiogenesis [331]. Another paper showed that topical and oral application of fucoxanthin  
to UVB-irradiated male hairless mice exhibited anti-melanogenic activity via suppression of PGs 
synthesis and expression of melanogenic receptors in melanocytes [332]. 
In conclusion, the use of carotenoids in the diet in combination with topical application may play an 
important role in skin photoprotection, thus being a useful strategy for treatment of skin diseases 
caused by excessive sun exposure. 
4.2.2. Fatty Acids 
As mentioned above, it is well known that PUFAs play important roles in many physiological and 
pathological processes. In the last years, their protective effects on acute and chronic skin diseases 
have been described, which are related to modulation of membrane fluidity and immune function, 
contribution to barrier integrity, promotion of wound healing and inhibition of eicosanoids and 
cytokines production, among others [333–337].  
Previous in vitro studies have shown the anti-inflammatory effects of n-3 PUFAs, like EPA or 
DHA, in skin cells through inhibition of the production of UVB- and TNF-α-induced IL-8 in HaCaT 
keratinocytes and CCD922SK fibroblast cell line [338]. Similarly, the treatment of human 
keratinocytes with n-3 PUFAs through liposomes based on a natural marine lipid extract reduced the 
croton oil-induced inflammatory response by downregulating PGE2 and IL-8 levels [339]. It has been 
suggested that the induction of COX-2 by EPA in HaCaT keratinocytes, via peroxisome proliferator-
activated receptor gamma (PPARγ) activation, may have an important role in the anti-inflammatory 
and protective mechanism of action of PUFAs [340]. Conversely, Obata et al. [341] described that 
EPA reduced expression of COX-2 and the subsequent PGD2 generation in human mast cells. On the 
other hand, n-6 PUFAs were shown to increase PGE2 levels, which was related with keratinocytic skin 
cancer growth [342,343]. Another mechanism involved in the anti-inflammatory effect of EPA 
includes the inhibition of ERK and JNK in HaCaT cell line, resulting in decreased MMP-1  
expression [344]. A recent study describes that EPA increases the expression of aquaporin-3, a 
water/glycerol transport protein, in HaCaT cells through ERK activation, leading to a reduction in 
UVB-induced photodamage [345]. 
The anti-inflammatory activity of PUFAs has also been reported in different in vivo skin models.  
In hairless mice, topical treatment with the n-3 PUFA 11,14,17-eicosatrienoic acid for 3 days reduced 
UV-induced epidermal and dermal thickness and inflammatory cell infiltration, as well as attenuated 
the expression of IL-1β, COX-2 and MMP-13 [346]. In a recent study, rats receiving oil mixes with  
n-9, n-6 and n-3 PUFAs and subjected to thermal burn showed a reduction of the thermal lesions and  
a decrease in NF-κB activity and cell proliferation [347]. As regards to cancer, the effects of high-fat 
diets rich in n-6 PUFAs or n-3 PUFAs were evaluated on UVB-induced skin carcinogenesis in hairless 
mice. The results reported an enhanced tumorigenesis in mice fed n-6 PUFAs; on the contrary, animals 
receiving n-3 PUFAs presented a reduced tumor incidence and multiplicity [348,349].  
Different clinical studies have reported that supplementation with PUFAs protects the skin against 
UV-induced erythema. A double-blind, randomized study reported that the oral administration of EPA 
for 3 months reduced UVB-induced PGE2 levels in healthy skin [350]. More recently, it has been 
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shown that EPA-rich n-3 PUFAs abrogated photoimmunosuppression in human skin, reduced sunburn 
sensitivity and prevented DNA damage, providing support for their chemopreventive role [351,352]. 
These authors conducted another double-blind, randomized controlled study to evaluate the  
mechanisms underlying the photoprotective effect of EPA. Supplementation with this PUFA for  
12 weeks increased the ratio EPA/AA in the skin, shifting eicosanoid production towards less  
pro-inflammatory mediators [353]. 
A prospective cohort study evaluated associations between plasma phospholipid levels of n-3 and  
n-6 PUFAs and the development of NMSC. The results showed a reduced risk of SCC in patients with 
high EPA concentrations and omega-3/-6 ratio and an inverse association of total omega-6 and BCC  
risk [354]. However, a study of over 40,000 American male health professionals failed to find a link 
between n-3 PUFA intake and BCC risk [355]. In conclusion, the photoprotective potential of  
n-3 PUFAs against UV radiation-induced inflammation and potentially longer-term photodamage 
should be further explored. 
4.2.3. Glycolipids 
Glycoglycerolipids such as MGDG, DGDG and SQDG can be widespread in microalgae, as 
previously mentioned. In general, they have demonstrated to have remarkable biological effects, 
including inhibition of in vitro and in vivo tumor-promoting-activity [356] as well as anti-inflammatory 
and immunosuppressive effects [357]. 
The effects of microalgae glycolipids against skin inflammation and cancer have been largely 
studied, and their mechanisms have been suggested by using in vitro cell cultures as well as in vivo 
animal models. A previous in vitro study demonstrated that pretreatment with glycoglycerolipid 
analogues was able to diminish phorbol 12-myristate 13-acetate (PMA)-promoted tumorigenicity in 
human dermal fibroblasts through protein kinase C (PKC)-dependent mechanisms [358]. 
In addition, these compounds have been demonstrated to have anti-inflammatory activity in vivo. 
The effects of different glycoglycerolipids from the thermophilic blue-green alga ETS-05 were 
evaluated in croton-oil-induced ear edema and carrageenan-induced paw edema models. Topical  
pre-treatment with MGDG, DGDG and SQDG inhibited the croton-oil-induced edema, with MGDG 
being the most potent anti-inflammatory glycolipid. Similarly, these findings were confirmed in the 
carrageenan-induced paw edema model [357]. 
As regards to skin cancer, Colombo et al. [359] evaluated the antitumoral activity of 
glycoglycerolipids analogues in an in vivo two-stage mouse skin carcinogenesis model, using DMBA 
as an initiator and TPA as a promoter. All compounds tested delayed the formation of papillomas and 
reduced the number of papillomas per mouse. More recently, these authors confirmed the  
antitumor-promoting effects of other synthetic glycoglycerolipids on mouse skin in the same  
model [208]. Currently, this kind of natural compounds could have a promising employment in the 
field of prevention or treatment of cancer. 
4.2.4. Polyssacharides 
Revising literature, there is only one paper showing the anti-inflammatory properties of sulfated 
polysaccharides derived from red microalgae in in vitro and in vivo models of skin inflammation.  
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The in vitro assay showed that these polysaccharides suppressed polymorphonuclear leukocyte 
migration and partially inhibited their adhesion to endothelial cells. In human volunteers, topical 
application of polysaccharide material inhibited cutaneous erythema induced by a known irritant [64]. 
4.2.5. Proteins 
As mentioned above, microalgae are considered an important source for protein production. 
Phycobiliproteins from Spirullina platensis have been shown to have important activities, including 
antioxidant, anti-inflammatory and neuroprotector [360,361] actions. In this regards, the 
phycobiliprotein C-phycocyanin isolated from Spirulina platensis prevented TPA-induced tumor 
promotion in mouse skin through reduction in COX-2, IL-6 and pSTAT3 expression [362].  
Some photosynthetic marine organisms have evolved mechanisms to counteract UV-radiation by 
synthesizing UV-absorbing compounds, called mycosporine-like amino acids (MAAs). MAAs from 
marine organisms, with only two exceptions, are imine derivatives of mycosporines that contain an 
amino-cyclohexenimine ring linked to an amino acid, amino alcohol or amino group [363], and they 
are biosynthesized by shikimic acid pathway for the synthesis of aromatic amino acids [364].  
In addition, MAAs have been identified in a number of taxonomically diverse organisms such as fungi, 
eukaryotic marine invertebrates and a wide variety of other marine organisms [365]. Around  
20 members can be found in the MAA family, including mycosporine-glycine, palythine, palythinol, 
asterina-330, porphyra-334 and shinorine. In microalgae species, shinorine is the most frequent  
and abundant MAA [366]. MAAs have been reported to have a high photostability [367], acting  
as endogenous antioxidant that protect microalgae against UV-induced damage [368–370]. The  
anti-photoaging role of MAAs has been evaluated in different skin cell lines. In this regards, porphyra-334 
from Porphyra (P.) yezoensis inhibited ROS production and MMPs expression in UVA irradiated 
human skin fibroblasts [371]. Recently, MAAs isolated from the marine green alga Chlamydomonas 
hedleyi have demonstrated to have anti-inflammatory activity in HaCat cells, by reducing COX-2 and 
involucrin expression [372]. 
4.2.6. Other Compounds 
Due to their antioxidant activity, phenolic and phenolic-derived compounds, which can be obtained 
from microalgae [73–75], could be used to control the inflammatory response of the skin to solar 
radiation and to prevent skin cancer. The structures of natural polyphenols vary from simple molecules 
(such as phenolic acids) and other simple polyphenolic compounds (such as flavonoids), to the more 
complex phlorotannins, which consist of polymeric structures made up of units of phloroglucinol  
(1,3,5-trihydroxybenzene), typically isolated from marine brown algae or Phaeophyceae [373]. Many of 
them have been reported to show anti-melanoma or anti-skin cancer activities [374]. For example, 
dietary feeding and topical application of brown algae polyphenols had a protective effect against 
UVB radiation-induced skin carcinogenesis in SKH-1 mice [375]. Polyphenol-containing aqueous 
methanol extract of the red alga Porphyra yezoensis was shown to modulate viability and apoptosis of 
the UVB-exposed HaCaT cells [376]. With respect to phlorotanins, their capacity to inhibit UV-induced 
oxidative stress and gelatinase activity makes them potential anti-photoaging agents [377].  
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Microalgae have been shown to be an important source of tocopherol, a fat-soluble phenolic 
compound with varying degrees of vitamin E antioxidant activity [378,379]. A previous in vitro study 
showed that tocopherol decreased cell proliferation and activation of MAPKs and NF-κB signaling 
induced by argemone oil in HaCaT cells [380]. γ-tocopherol has been shown to have the most important 
anti-inflammatory activity and it can reduce PGE2 levels in vitro [381] and in vivo [382,383].  
A hydrophilic γ-tocopherol derivative, γ-tocopherol-N, N-dimethylglycinate hydrochloride, reduced 
photoinflammation in mouse skin, by decreasing COX-2 expression [384]. 
The anti-inflammatory and antitumoral effects of tocopherol have also been reported in different 
animal models. Topical administration of d-α-tocopherol acetate to the skin of hairless mice reduced 
erythema, edema and skin sensitivity associated with UVB-induced sunburn [385]. Moreover, vitamin E 
application 30 minutes prior to TPA treatment suppressed early inflammatory and oxidative stress 
responses induced by TPA through inhibition of H2O2, MPO activity and lipid peroxidation [386]. 
Regarding the tumor suppressive effects, topical application of vitamin E to mice for 3 weeks prior to 
UV irradiation reduced cancer formation and immunosuppression by UV radiation in hairless mice [387]. 
Microalgae could provide a rich source of ascorbic acid in our diet, despite the differences in the 
composition found in microalgae species (0.11%–1.62% ascorbic acid) [388]. To solve the problem of 
its high instability, liposoluble vitamin C derivatives, such as tetra-isopalmitoyl ascorbic acid, are often 
used in dermocosmetic products [389]. In vitro studies have reported important biological activities for 
vitamin C. For example, vitamin C and vitamin E have shown to have preventive effects against 
deleterious cutaneous cell damage caused by a herbicide in HaCaT keratinocytes [390]. In addition, 
vitamin C antagonized UV-induced apoptosis and activated tumor suppressor genes in human skin 
cancer cells [391]. Ascorbic acid and its derivatives have been shown to protect against sunburn in 
mice, delay the onset of skin tumors and reduce UV-induced skin wrinkling [392]. 
Another of the main active compounds in marine micro and macroalgae include the sterols, such as 
fucosterol [393], which showed antioxidant activity and cytotoxicity against several cancer cell  
lines [394]. Fucosterol protected human dermal fibroblast against UVB-induced damage, decreasing 
the expression of MMP-1, IL-6 and other inflammatory markers, and increasing the production of type 
I procollagen and TGF-β1 [395,396]. These results suggest the potential of fucosterol for preventing 
skin ageing and development of skin cancer.  
5. Conclusions 
Numerous animal models and epidemiologic studies support the role of a deregulated inflammation 
in tumor development. In this regard, there are many triggers of chronic inflammation that increase the 
risk of cancer, such as immunological diseases (for example, IBD is associated with colon cancer) and 
cutaneous lesions associated with chronic exposure to UV radiation (for example, AK is related to skin 
cancer). There are two different pathways linking inflammation and cancer: an extrinsic pathway 
mediated by chronic inflammation and oxidative environment (inflammation-cancer) and an intrinsic 
pathway in which genetic mutations cause alterations in cell proliferation, reduction of apoptosis,  
or increase in metastasis and angiogenesis; these effects in the absence of an underlying inflammation, 
initiate a tumor-driven host immune response leading to a microenvironment composed of 
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inflammatory cells (cancer-inflammation). These data confirm the role of inflammatory processes in 
cancer origin and development. 
New strategies for the prevention and treatment of inflammatory diseases and associated colon and 
skin cancers should be an important focus in cancer research. A high number of in vitro and in vivo 
studies and some clinical data have established the antioxidant, anti-inflammatory and antitumor 
potentials of microalgae species and their products, including carotenoids, fatty acids, glycolipids, 
polysaccharides and proteins. In this line, the simple growth requirements of microalgae make them 
attractive to meet the demands of the pharmaceutical, food and cosmetic industry. Complementary 
basic studies and well-controlled randomized clinical trials are needed to establish the optimal dose for 
chemopreventive efficacy, excluding toxic effects, all with the objective to be validated for a good 
clinical practice. 
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